儿童克罗恩病早期使用5-氨基水杨酸增加激素暴露并降低生物制剂持久性
该前瞻性多中心起始队列研究纳入679例儿童克罗恩病患者,发现18%早期接受5-氨基水杨酸单药治疗。
要点
- 儿童克罗恩病早期5-氨基水杨酸单药治疗常见,但代表治疗不足。
- 早期5-氨基水杨酸与更多全身激素暴露和生物制剂延迟启动相关。
- 升级治疗者中,早期5-氨基水杨酸增加生物制剂停用风险(HR 4.47)。
核心结论
- 儿童克罗恩病早期使用5-氨基水杨酸常见且治疗不足,与更差结局相关,包括更多激素暴露、生物制剂延迟启动和生物制剂持久性降低,且不预防疾病并发症。
- 研究结果支持在儿童克罗恩病患者中避免使用5-氨基水杨酸,并优先早期抗TNF治疗以改善长期结局和降低肛周病变风险。
研究设计与样本
- 前瞻性、多中心起始队列研究,使用BISCUIT研究数据。
- 共纳入679例儿童克罗恩病患者,早期治疗定义为诊断后<90天,分组包括生物制剂、免疫调节剂、5-氨基水杨酸及以上均无。
- 主要结局为生物制剂持久性,次要结局包括糖皮质激素使用、治疗失败和疾病并发症。
- 采用稳定化逆概率治疗加权和Cox回归平衡组间基线差异。
主要发现
- 679例患者中18%接受早期5-氨基水杨酸单药治疗。
临床怎么用
- 儿童克罗恩病患者应避免早期使用5-氨基水杨酸单药治疗,因其代表治疗不足并与更差结局相关。
- 对儿童克罗恩病患者应优先考虑早期抗TNF治疗,以改善长期结局并降低肛周病变风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Despite lack of evidence for efficacy, 5-aminosalicylates (5-ASAs) continue to be prescribed for pediatric Crohn's disease (pCD). There are limited data examining current practice patterns in pCD and the impact of 5-ASAs use on clinical outcomes. We aimed to determine the prevalence of 5-ASAs use in pCD and evaluate its association with biologic durability, corticosteroid exposure, and disease-related complications. METHODS: We conducted a prospective, multicenter inception cohort study using data from the Biologic dISContinuation sTudy (BISCUIT). Early therapy (<90 days from diagnosis) groups included biologics, immunomodulators, 5-ASAs, and none of the above. The primary outcome was biologic durability. The secondary outcomes included corticosteroid use, therapy failure, and disease complications. Stabilized inverse probability of treatment weighting and Cox regressions were employed to equate for baseline differences among groups. RESULTS: Of 679 patients, 18% received early 5-ASA monotherapy. Early 5-ASAs were associated with greater systemic corticosteroid use (P = .036) and delayed time-to-biologic (median, ∼11 months), with 58.0% of patients escalating therapy. Among those who escalated, early 5-ASAs increased the risk of biologic discontinuation (hazard ratio, 4.47; 95% confidence interval, 1.28-15.65; P = .029). Furthermore, early 5-ASA and immunomodulator use did not prevent disease complications, whereas early anti-tumor necrosis factor therapy protected against perianal disease (odds ratio, 0.24; 95% confidence interval, 0.06-0.93; P = .039). CONCLUSIONS: Early 5-ASAs use in patients with pCD is common, represents undertreatment, and is associated with inferior outcomes, including greater steroid exposure, delayed initiation of effective biologic therapy, and decreased biologic durability, without protection against disease complications. These findings support avoidance of 5-ASAs in patients with pCD and prioritizing early anti-tumor necrosis factor therapy to improve long-term outcomes and reduce perianal disease risk.
引用
- Patel PV, Moses J, Ali S, et al. Aminosalicylate Use Increases Corticosteroid Exposure and Decreases Biologic Durability in Pediatric Crohn's Disease. Clin Gastroenterol Hepatol. 2026. PMID: 42628666. doi:10.1016/j.cgh.2026.08.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。